Results of multi-centre monitoring of sibutramine treatment in obese diabetic patients in Czech Republic

Česká verzia

Authors: A. Šmahelová
Authors place of work: Klinika gerontologická a metabolická Lékařské fakulty UK a FN, Hradec Králové, přednosta prof. MUDr. Luboš Sobotka, CSc.
Published in the journal: Vnitř Lék 2005; 51(6): 676-680
Category: Original Contributions

Summary

Sibutramine is a very effective antiobesitic drug in the present. It has weight reducing, global metabolic and antidiabetic effects. To verify and to get the experiences with practical use of sibutramin in Type 2 diabetics in the Czech Republic was the purpose of the clinical observation MERIDIOS I.

Patients and methods:
499 diabetics (average age 52.4 ± 9,5 years) were included, to the statistical evaluation after 3 months of the therapy Wilcoxon rank sum test was used. 308 (61,7%) diabetics took oral antidiabetic agents. 424 (83%) diabetics used antihypertensive drugs, 384 (75%) hypolipidemic agents. 275 (55.1%) diabetics took sibutramine in the dose 10 mg once a day, 224 (44.9%) diabetics in the dose 15 mg once a day.

Results:
The average weight loss was 6.1 kg (p < 0.001). Waist circumference diminished about 4.7 cm (p < 0.001), glycosylated hemoglobin about 0.75% (p < 0.001), systolic blood pressure about 5.2 mm Hg (p < 0.001), diastolic blood pressure about 3.1 mm Hg (p < 0.001) in average. The daily dosage of oral antidiabetic agents diminished in 33.1% of all included diabetics. Any serious adverse events of sibutramine were recorded.

Conclusion:
Significant weight loss, diminished waist circumference and blood pressure, improvement of diabetes compensation and lower daily dose of oral hypoglycemic agents were observed in obese Type 2 diabetics after 3 months therapy with sibutramine in the dose 10 or 15 mg per day.

Key words:
diabetes mellitus type 2 – sibutramin – obesity

Zdroje

1. Avenell A, Brown TJ, McGee MA et al. What interventions should we add to weight reducing diets in adults with obesity? A systematic reviw of randomized controlled trials of adding drug therapy, exercise, behaviour therapy or combinations of these interventions. J Hum Nutr Diet 2004; 17: 293–316.

2. Svačina Š, Owen K. Obezita, diabetes 2. typu a jejich kvantitativní vztahy. Vnitř Lék 2002; 48: 500–506.

3. Atkinson RL. Clinical guidelines on the indentification, evaluation, and pharmacologic treatment of obesity in adults. Endotext Com 2003; 25: Ch 15b.

4. Fujioka K, Seaton TB, Rowe E et al. Weight loss with sibutramine improves glycemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. Diabetes Obes Metab 2000; 2: 175–187.

5. Gokcel A, Karakose H, Ertorer EM et al. Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control. Diabetes Care 2001; 24: 1957–1960.

6. Derosa G, Cicero AF G et al. Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients. Diabetes Nutr Metab 2004; 17: 222–229.

7. Goldstein BJ, Muller–Wieland D. Textbook of Type 2 Diabetes. London: Martin Dunitz 2003.

8. Hauner H, Meier M, Wendland G et al. SAT Study. Weight reduction by sibutramine in obese subjects in primary care medicine: the SAT study. Exp Clin Endocrinol Diabetes 2004; 112: 201–207.

9. UKPDS Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). Brit Med J 1998; 317: 703–713.

10. Van Gaal LF, Wauters MA, Peiffer FW et al. Sibutramine and fat distribution: is there a role for pharmacotherapy in abdominal/visceral fat reduction? Int J Obesity 1998; 22(Suppl 1): S38–S40; discussion S41–S42.

11. McNulty SJ, Williams GA. Randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin. Diabetes Care 2003; 26: 125–131.

12. Serrano-Rios M, Melchionda N, Moreno-Carretero E. Role of sibutramine in the treatment of obese type 2 diabetic patients receiving sulphonylurea therapy. Diabet Med 2002; 19: 119–124.